IDEAYA Biosciences, Inc. IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

IDYA

Hisse Senetlerindeki Sıralama #4548
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Hisse Fiyatı
$35.22
Piyasa Değeri
$3.40B
Değişim (1 gün)
4.17%
Değişim (1 yıl)
15.44%
Ülke
US
Ticaret IDEAYA Biosciences, Inc. (IDYA)

Kategori

Healthcare
IDEAYA Biosciences, Inc. (IDYA) için hisse bölünme geçmişi
IDEAYA Biosciences, Inc. hissesi (sembol: IDYA) toplamda 0 hisse bölünmesi yaşamıştır.
En son hisse bölünmesi Oct 20, 2026 tarihinde gerçekleşmiştir.
Oct 20, 2026 tarihinden önce alınan bir IDYA hissesi bugün 0 IDYA hissesine eşdeğerdir.
Hisse bölünme listesi
Yıl Bölünme Çarpan Kümülatif Çarpan
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için hisse bölünmeleri
Şirket Hisse bölünme sayısı Kümülatif Çarpan Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL